Metformin (generic), Glucophage News

On April 15, the US Food and Drug Administration approved the once-weekly injectable Type 2 diabetes medicine albiglutide , developed by GlaxoSmithKline .

The once-weekly therapy is indicated, in conjunction with diet and exercise, to improve glycemic control.

Dr. Troy Harkness has received a Canadian Cancer Society Innovation Grant to investigate a new strategy to overcome treatment resistance in cancers.

MicroBiome Therapeutics LLC ' Clinical Trial Data For NM504 In Type 2 Diabetes Has Been Accepted For Presentation At ICE/ENDO 2014 /PRNewswire/ -- MicroBiome TherapeuticsTM LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster ... (more)

We are often warned that supplements can be dangerous when mixed with medication.

Cancer research is being conducted at the University of Saskatchewan veterinary college using dogs.

Researchers at the University of Saskatchewan are hoping to learn more about extending the lives of people with drug resistant cancer by extending the lives of dogs.

A drug commonly used to treat diabetes does not help prevent heart failure in non-diabetics who've had a heart attack, according to a new study.

The use of metformin, a common regulator of blood glucose for diabetics, does not help protect against heart failure in non-diabetic patients who have suffered a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

Although some research has suggested that metformin, a medication often used in the treatment of diabetes, may have favorable effects on ventricular function, among patients without diabetes who underwent percutaneous coronary intervention for ST-segment elevation myocardial infarction , treatment with metformin did not result in improved ... (more)

New research sends a stark warning to overweight teens: If you develop diabetes, you'll have a very tough time keeping it under control.

GSK receives European authorisation for once-weekly type 2 diabetes treatment, EperzanA 26 March 2014, London UK -- GlaxoSmithKline plc today announced that the European Commission has granted marketing authorisation for its once-weekly diabetes treatment, EperzanA .

Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview on Boston Therapeutics, Inc. .

Of the estimated 20.6 million individuals with diabetes, approximately thirty percent of them are undiagnosed.